Trials / Completed
CompletedNCT00332969
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate the efficacy of treatment with octroetide in patients with primary inoperable thymoma to reduce tumor size.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Octreotide |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2010-10-01
- First posted
- 2006-06-02
- Last updated
- 2017-03-31
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00332969. Inclusion in this directory is not an endorsement.